Welcome to our dedicated page for Theravance Biopharma news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Biopharma stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's mission is to pioneer a new generation of small-molecule drugs that better meet patient needs by maximizing efficacy while limiting systemic side effects.
Theravance Biopharma has a strong focus on inflammation and immunology and aims to deliver Medicines that Make a Difference® in people's lives. The company's research expertise has led to the development of the FDA-approved YUPELRI® (revefenacin) inhalation solution, the first once-daily, nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Theravance Biopharma co-promotes YUPELRI with Viatris Inc. under a profit and loss sharing arrangement.
Another promising product in Theravance Biopharma's pipeline is ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). This drug has the potential to be a first-in-class therapy, addressing a significant unmet medical need for MSA patients.
The company is also involved in strategic collaborations with other pharmaceutical companies to expand its reach and enhance its product pipeline. Their current projects and partnerships are aimed at furthering the development and commercialization of innovative therapies.
Financially, Theravance Biopharma has shown consistent performance, with significant growth in YUPELRI net sales and robust clinical trial activity. Recent achievements include positive results from a Phase III clinical trial of YUPELRI in China and ongoing enrollment in the Phase 3 CYPRESS study for ampreloxetine. These milestones underscore the company's commitment to delivering impactful therapies and driving shareholder value.
Theravance Biopharma continues to leverage its organ-selective drug development expertise to create value and improve patient outcomes. For more information, please visit www.theravance.com.
Theravance Biopharma (NASDAQ: TBPH) has announced that its management team will be conducting investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, CA. Interested investors can request one-on-one meetings with the management team by contacting the company's investor relations department.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will engage in a Fireside Chat on Tuesday, December 3 at 11:15 am EST, alongside hosting in-person meetings with the investment community. The event will be accessible via webcast on Theravance.com under the Investors section, with a replay available for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) reported Q3 2024 results, highlighting strong performance in key areas. YUPELRI net sales reached $62.2M, a 7% YoY increase and 14% QoQ growth. TRELEGY sales hit $789M, up 17% YoY. The company formed a Strategic Review Committee to explore alternatives for unlocking shareholder value. R&D expenses were $9.3M, while SG&A expenses stood at $16.9M. A non-cash impairment charge of $1.6M was recorded. Net loss was $12.7M, impacted by the impairment. Cash reserves totaled $91.4M. The company expects R&D expenses of $30-36M and SG&A expenses of $45-55M for full-year 2024. A settlement agreement with Qilu resolved ongoing patent litigation over YUPELRI.
Theravance Biopharma (NASDAQ: TBPH) has scheduled its third quarter 2024 financial results announcement and business update for November 12, 2024, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EST on the same day. Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through Theravance's website. A replay will be available online for 30 days until December 12, 2024.
Theravance Biopharma announced the publication of a sub-study of pivotal Phase 3 trials for YUPELRI (revefenacin), the first FDA-approved once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD. The study, published in the International Journal of Chronic Obstructive Pulmonary Disease, evaluated the area under the curve (AUC) lung function effects in moderate-to-very-severe COPD patients.
Key findings include:
- Revefenacin improved bronchodilation versus placebo in COPD patients
- Rapid onset of bronchodilation was observed, with a mean FEV1 difference of 145 mL at 15 minutes
- Day 84 bronchodilation improvements were sustained over 24 hours vs. placebo
- FEV1 AUC measurements provide additional information on the magnitude and consistency of bronchodilation throughout the dosing interval
The study reinforces that YUPELRI provides consistent and durable improvements in lung function over a full 24-hour period.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company will engage in a Fireside Chat on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST). Additionally, Theravance Biopharma will host in-person meetings with the investment community during the conference.
Investors and interested parties can access a webcast of the event through the company's website, Theravance.com, under the Investors section, Events and Presentations. The webcast replay will be available on the company's website for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.
Theravance Biopharma reported Q2 2024 financial results and provided a business update. YUPELRI net sales decreased 1% to $54.5 million, while Viatris collaboration revenue increased 4% to $14.3 million. The company updated its timeline for the CYPRESS study, now expecting the last patient enrollment in mid-2025. TRELEGY net sales reached $1.065 billion, increasing the likelihood of achieving up to $50 million in milestones in 2024. Theravance ended Q2 with a cash balance of $96.1 million. The company is exploring opportunities to unlock value from its Irish tax assets and has updated its 2024 financial guidance.
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). In addition to the chat, Theravance Biopharma's senior management team will be available for one-on-one meetings with investors during the conference.
Interested parties can access the webcast or schedule meetings with the management team by contacting their BTIG representative or emailing uscorporateaccess@btig.com. This event provides an opportunity for investors to gain insights into Theravance Biopharma's current activities and future plans directly from the company's leadership.
Theravance Biopharma (NASDAQ: TBPH) has announced that it will release its second quarter 2024 financial results after market close on August 5, 2024. The company will also provide a business update during this report. Following the release, Theravance Biopharma will host a conference call and simultaneous webcast at 5:00 pm ET (2:00 pm PT/10:00 pm IST) on the same day.
Interested parties can pre-register for the telephone conference call or access the live webcast through the Investors section of Theravance Biopharma's website. A replay of the webcast will be available on the company's website for 30 days, until September 4, 2024.
Theravance Biopharma (NASDAQ: TBPH) reported first-quarter 2024 financial results, highlighting YUPELRI® sales of $55.2 million, an 18% increase year-over-year. Collaboration revenue with Viatris rose by 39% to $14.5 million. The company's Q1 ending cash balance was $100 million. R&D and SG&A expenses decreased to $9 million and $16.7 million, respectively. Theravance also reported a net loss of $11.7 million, down from $22.1 million in Q1 2023. The company is progressing with the CYPRESS study for ampreloxetine and has a key opinion leader event scheduled for May 23, 2024.
FAQ
What is the current stock price of Theravance Biopharma (TBPH)?
What is the market cap of Theravance Biopharma (TBPH)?
What is Theravance Biopharma's primary focus?
What is YUPELRI?
What is ampreloxetine?
Who are Theravance Biopharma’s strategic partners?
What recent achievements has Theravance Biopharma made?
Where can I find more information about Theravance Biopharma’s products?
What is the purpose of the CYPRESS study?
How does Theravance Biopharma create shareholder value?
What is Theravance Biopharma’s mission?
How can I listen to Theravance Biopharma's conference calls?
